Clopidogrel Tablet
Product Images NDC 67296-2266

Product Visual Gallery

This gallery contains 18 technical images submitted to the FDA as part of the official labeling for Clopidogrel (NDC 67296-2266). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Redpharm Drug, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

505 (Clopidogrel 1000s)

Label for Clopidogrel Tablets, USP 75 mg oral tablets. The label states each tablet contains 97.875 mg clopidogrel bisulfate equivalent to 75 mg clopidogrel base. It includes storage instructions and dispensing warnings. Manufactured by Macleods Pharmaceuticals Ltd. in India and marketed by NorthStar Rx LLC. The label also features barcodes and indicates a package size of 1000 tablets.*

FDA Label Image

505 (Clopidogrel 75mg 30s)

Clopidogrel Tablets, USP 75 mg oral tablets label by NorthStar Drug. The label shows the NDC 16714-052-01, package count of 30 tablets, storage instructions, and manufacturer information including NorthStar Rx LLC and Macleods Pharmaceuticals Ltd., India. It indicates that dosage details are in the package insert.*

FDA Label Image

505 (Clopidogrel 75mg 500s)

Label for Clopidogrel Tablets, USP 75 mg oral tablets. The label includes dosage strength, storage instructions, pharmacist dispensing advisory, and manufacturer information. It shows the product NDC as 16714-052-03 with a package count of 500 tablets. Manufactured by Macleods Pharmaceuticals Ltd., India, for NorthStar Rx LLC.*

FDA Label Image

505 (Clopidogrel 75mg 90s)

Label for Clopidogrel Tablets, USP 75 mg, showing details for a bottle of 90 tablets. The label includes dosage information stating each tablet contains 75 mg of clopidogrel base, storage instructions, and a pharmacist dispensing note. The label lists the manufacturer as Macleods Pharmaceuticals Ltd., located in India, with distribution by NorthStar Rx in Memphis, TN. Several barcodes and product codes are also present.*

FDA Label Image

189 (Clopidogrel Fig 3)

A forest plot chart depicting subgroup analysis of Clopidogrel versus placebo. The chart shows hazard ratios with 95% confidence intervals for various subgroups, including Heparin/LMWH, Aspirin dosage levels, GPIIb/IIIa antagonist use, Beta-blocker use, and ACE inhibitor use. The overall comparison is included, illustrating the relative effect of Clopidogrel compared to placebo on the hazard ratio scale.*

FDA Label Image

Figure-1 (Clopidogrel Figure 01)

A horizontal bar plot showing the effect of co-administered proton pump inhibitors (PPIs) on the active metabolite area under the curve (AUC) of Clopidogrel. The plot compares Dexlansoprazole 60 mg, Lansoprazole 30 mg, Pantoprazole 80 mg, and Omeprazole 80 mg, illustrating mean values and 90% confidence intervals for changes relative to Clopidogrel administered alone.*

FDA Label Image

Figure-2 (Clopidogrel Figure 02)

This is a line graph depicting the cumulative event rate (%) of cardiovascular death, myocardial infarction, and stroke over 12 months of follow-up. It compares two groups: one receiving Clopidogrel with aspirin, and the other receiving placebo with aspirin. The graph shows a lower event rate for the Clopidogrel group throughout the follow-up period, with statistical significance indicated by a p-value of 0.00009.*

FDA Label Image

Figure-4 (Clopidogrel Figure 04)

A Kaplan-Meier survival curve chart showing the percentage of patients who died before first discharge over time (up to 28 days) comparing outcomes between Clopidogrel and placebo groups. It includes data on death counts and notes a 7% proportional risk reduction with Clopidogrel.*

FDA Label Image

146 (Clopidogrel Figure 05)

A Kaplan-Meier curve showing the percentage of patients with death, reinfarction, or stroke before first discharge over 28 days since randomization, comparing Clopidogrel versus placebo. The graph indicates lower event rates for Clopidogrel with a 9% proportional risk reduction (p = 0.002).*

FDA Label Image

Fig-7 (Clopidogrel Figure 07)

A line graph showing the cumulative event rate percentage of fatal or non-fatal vascular events over months of follow-up, comparing Aspirin and Clopidogrel. The x-axis represents months from 0 to 36, and the y-axis shows cumulative event rate from 0% to 16%. The graph includes a p-value of 0.045 indicating statistical comparison.*

FDA Label Image

Figure-3 (Clopidogrel Figure 3)

A forest plot showing hazard ratios with 95% confidence intervals across various subgroups comparing Clopidogrel versus placebo. Subgroups include age, gender, race, elevated cardiac enzymes, diabetes, previous myocardial infarction, and previous stroke, along with overall results. The plot visualizes whether outcomes favor Clopidogrel or placebo for each subgroup.*

FDA Label Image

Figure-6 (Clopidogrel Figure 6)

A forest plot chart showing odds ratios (with 99% confidence intervals) comparing the effects of Clopidogrel versus placebo across various subgroups such as gender, age, hours since onset, systolic blood pressure, heart rate, and fibrinolytic agent use. The plot visually indicates whether the data favors Clopidogrel or placebo for each subgroup and overall.*

FDA Label Image

Figure-8 (Clopidogrel Figure 8)

A forest plot depicting hazard ratios with 95% confidence intervals comparing Clopidogrel and Aspirin across qualifying conditions of Stroke, MI (Myocardial Infarction), and PAD (Peripheral Artery Disease), plus an overall comparison. The x-axis shows hazard ratios ranging from 0.6 to 1.3, indicating favor towards Clopidogrel or Aspirin for each condition.*

FDA Label Image

Structure (Clopidogrel Structure)

Chemical structure of clopidogrel shown as a two-dimensional molecular diagram, including a bicyclic ring with sulfur, a chlorophenyl group, and attached functional groups representing the active ingredient clopidogrel bisulfate.*

FDA Label Image

505 (Clopidogrel Tablets 30s Daman)

Clopidogrel Tablets USP 75 mg oral tablet label from NorthStar, indicating a package size of 30 tablets. The label includes storage instructions, barcode, and manufacturer information showing Macleods Pharmaceuticals Ltd., India, with a note for pharmacists to dispense the medication guide.*

FDA Label Image

505 (Clopidogrel Tablets 500s Daman)

Clopidogrel Tablets USP 75 mg oral tablet packaging label showing a 500 tablet count. Includes dosage information, storage instructions, and manufacturer details for NorthStar Rx LLC and Macleods Pharmaceuticals Ltd. The label indicates that the medication guide should be dispensed separately to patients and includes barcodes and regulatory information.*

FDA Label Image

505 (Clopidogrel Tablets 90s Daman)

The label for Clopidogrel Tablets, USP 75 mg features a blue and white design with the NDC 16714-052-02. It indicates 90 tablets per package and includes instructions for pharmacists to dispense the Medication Guide separately. The label lists storage conditions, barcode, manufacturer details Macydo Pharmaceuticals Ltd and NorthStar Rx LLC, and notes the product is made in India.*

FDA Label Image

505 (Clopidogrel Tablets Carton)

Packaging label for Clopidogrel Tablets, USP 75 mg oral tablets by NorthStar Rx. The box contains 100 tablets (10 x 10 unit dose). The label includes storage instructions, manufacturer details (Macleods Pharmaceuticals Ltd., India), and a note for pharmacists to dispense the medication guide.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.